The NAA10 antibody is a crucial tool for studying the N-terminal acetyltransferase A (NatA) complex, which plays a pivotal role in co-translational protein modification. NAA10. also known as ARD1. is the catalytic subunit of NatA and mediates the acetylation of approximately 40% of human proteins, influencing protein stability, localization, and interactions. This enzyme is evolutionarily conserved and ubiquitously expressed, underscoring its fundamental role in cellular processes such as cell cycle regulation, apoptosis, and metabolism.
NAA10 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression levels, subcellular localization, and post-translational modifications. Dysregulation of NAA10 has been implicated in various diseases, including cancers (e.g., breast, liver, and colorectal tumors), where it may act as either an oncogene or tumor suppressor depending on context. Its dual role in cancer progression remains an active research area, with studies suggesting links to hypoxia response, angiogenesis, and metastasis.
Additionally, NAA10 mutations are associated with developmental disorders such as Ogden syndrome, characterized by cardiac arrhythmias and growth delays. Researchers utilize NAA10 antibodies to explore its pathological mechanisms and therapeutic potential. However, challenges persist in distinguishing NAA10 isoforms and differentiating its acetyltransferase activity from non-catalytic functions. Validated antibodies are essential for clarifying these complexities and advancing precision medicine approaches targeting protein acetylation pathways.